These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

506 related articles for article (PubMed ID: 18167109)

  • 21. Evaluation of strontium 90 irradiation in treatment of cutaneous mast cell tumors in cats: 35 cases (1992-2002).
    Turrel JM; Farrelly J; Page RL; McEntee MC
    J Am Vet Med Assoc; 2006 Mar; 228(6):898-901. PubMed ID: 16536702
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Response of canine mast cell tumors to treatment with oral prednisone.
    McCaw DL; Miller MA; Ogilvie GK; Withrow SJ; Brewer WG; Klein MK; Bell FW; Anderson SK
    J Vet Intern Med; 1994; 8(6):406-8. PubMed ID: 7884726
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of surgical margins required for complete excision of cutaneous mast cell tumors in dogs.
    Simpson AM; Ludwig LL; Newman SJ; Bergman PJ; Hottinger HA; Patnaik AK
    J Am Vet Med Assoc; 2004 Jan; 224(2):236-40. PubMed ID: 14736068
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of primary re-excision after recent inadequate resection of soft tissue sarcomas in dogs: 41 cases (1999-2004).
    Bacon NJ; Dernell WS; Ehrhart N; Powers BE; Withrow SJ
    J Am Vet Med Assoc; 2007 Feb; 230(4):548-54. PubMed ID: 17302554
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A phase II study to evaluate the toxicity and efficacy of alternating CCNU and high-dose vinblastine and prednisone (CVP) for treatment of dogs with high-grade, metastatic or nonresectable mast cell tumours.
    Rassnick KM; Bailey DB; Russell DS; Flory AB; Kiselow MA; Intile JL; Malone EK; Balkman CE; Barnard SM
    Vet Comp Oncol; 2010 Jun; 8(2):138-52. PubMed ID: 20579327
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Recurrence rates and sites for grade II canine cutaneous mast cell tumors following complete surgical excision.
    Weisse C; Shofer FS; Sorenmo K
    J Am Anim Hosp Assoc; 2002; 38(1):71-3. PubMed ID: 11804319
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Principles of treatment for mast cell tumors.
    Govier SM
    Clin Tech Small Anim Pract; 2003 May; 18(2):103-6. PubMed ID: 12831070
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognosis following surgical excision of canine cutaneous mast cell tumors with histopathologically tumor-free versus nontumor-free margins: a retrospective study of 31 cases.
    Michels GM; Knapp DW; DeNicola DB; Glickman N; Bonney P
    J Am Anim Hosp Assoc; 2002; 38(5):458-66. PubMed ID: 12220031
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Iridium-192 interstitial brachytherapy as adjunctive treatment for canine cutaneous mast cell tumors.
    Northrup NC; Roberts RE; Harrell TW; Allen KL; Howerth EW; Gieger TL
    J Am Anim Hosp Assoc; 2004; 40(4):309-15. PubMed ID: 15238561
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The tyrosine kinase inhibitor imatinib [STI571] induces regression of xenografted canine mast cell tumors in SCID mice.
    Kobie K; Kawabata M; Hioki K; Tanaka A; Matsuda H; Mori T; Maruo K
    Res Vet Sci; 2007 Apr; 82(2):239-41. PubMed ID: 16919303
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The prognostic value of lymph node metastasis with grade 2 MCTs in dogs: 55 cases (2001-2010).
    Baginski H; Davis G; Bastian RP
    J Am Anim Hosp Assoc; 2014; 50(2):89-95. PubMed ID: 24446400
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Outcome of dogs with mast cell tumors in the inguinal or perineal region versus other cutaneous locations: 124 cases (1990-2001).
    Sfiligoi G; Rassnick KM; Scarlett JM; Northrup NC; Gieger TL
    J Am Vet Med Assoc; 2005 Apr; 226(8):1368-74. PubMed ID: 15844431
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Multicenter prospective trial of hypofractionated radiation treatment, toceranib, and prednisone for measurable canine mast cell tumors.
    Carlsten KS; London CA; Haney S; Burnett R; Avery AC; Thamm DH
    J Vet Intern Med; 2012; 26(1):135-41. PubMed ID: 22176473
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A phase II clinical trial of vinorelbine in dogs with cutaneous mast cell tumors.
    Grant IA; Rodriguez CO; Kent MS; Sfilgoi G; Gordon I; Davis G; Lord L; London CA
    J Vet Intern Med; 2008; 22(2):388-93. PubMed ID: 18312556
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Proof of target for SU11654: inhibition of KIT phosphorylation in canine mast cell tumors.
    Pryer NK; Lee LB; Zadovaskaya R; Yu X; Sukbuntherng J; Cherrington JM; London CA
    Clin Cancer Res; 2003 Nov; 9(15):5729-34. PubMed ID: 14654558
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Results of radiation therapy in 19 dogs with cutaneous mast cell tumor and regional lymph node metastasis.
    Chaffin K; Thrall DE
    Vet Radiol Ultrasound; 2002; 43(4):392-5. PubMed ID: 12175005
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dose-escalating vinblastine for the treatment of canine mast cell tumour.
    Vickery KR; Wilson H; Vail DM; Thamm DH
    Vet Comp Oncol; 2008 Jun; 6(2):111-9. PubMed ID: 19178670
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Surgically planned versus histologically measured lateral tumor margins for resection of cutaneous and subcutaneous mast cell tumors in dogs: 46 cases (2010-2013).
    Risselada M; Mathews KG; Griffith E
    J Am Vet Med Assoc; 2015 Jul; 247(2):184-9. PubMed ID: 26133218
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A systematic review of surgical margins utilized for removal of cutaneous mast cell tumors in dogs.
    Selmic LE; Ruple A
    BMC Vet Res; 2020 Jan; 16(1):5. PubMed ID: 31906934
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mast cell tumor destruction by deionized water.
    Grier RL; Di Guardo G; Schaffer CB; Pedrosa B; Myers R; Merkley DF; Thouvenelle M
    Am J Vet Res; 1990 Jul; 51(7):1116-20. PubMed ID: 2117868
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.